Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s423. https://doi.org/10.25251/skin.8.supp.423